1. |
Coutant F, Miossec P. Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Curr Opin Rheumatol, 2020, 32(1): 57-63.
|
2. |
Schett G. Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis. Mod Rheumatol, 2017, 27(2): 193-197.
|
3. |
Meednu N, Zhang H, Owen T, et al. Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis. Arthritis Rheumatol, 2016, 68(4): 805-816.
|
4. |
Tanaka Y, Ohira T. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Curr Opin Pharmacol, 2018, 40: 110-119.
|
5. |
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 2009, 361(8): 756-765.
|
6. |
Hasegawa T, Kaneko Y, Izumi K, et al. Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. Joint Bone Spine, 2017, 84(3): 379-380.
|
7. |
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31(3): 315-324.
|
8. |
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010, 62(9): 2569-2581.
|
9. |
van der Heijde D, Simon L, Smolen J, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum, 2002, 47(2): 215-218.
|
10. |
张正付, 李萌, 燕娟, 等. 药物临床试验中不良事件的案例收集与评判. 中国临床药理学杂志, 2020, 36(23): 3957-3961.
|
11. |
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Available at: http://handbook.cochrane.org.
|
12. |
So H, Cheng IT, Lau SL, et al. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis, 2021, 80(8): 981-988.
|
13. |
Mochizuki T, Yano K, Ikari K, et al. Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: an open-label, randomized, pilot study. Osteoporos Sarcopenia, 2021, 7(3): 110-114.
|
14. |
Tanaka Y, Soen S, Ishiguro N, et al. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open, 2020, 6(2): e001249.
|
15. |
Takeuchi T, Tanaka Y, Soen S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis, 2019, 78(7): 899-907.
|
16. |
Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis, 2016, 75(6): 983-990.
|
17. |
Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 2010, 62(4): 569-574.
|
18. |
Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum, 2008, 58(5): 1299-1309.
|
19. |
Tanaka S, Tanaka Y. RANKL as a therapeutic target of rheumatoid arthritis. J Bone Miner Metab, 2021, 39(1): 106-112.
|
20. |
Tateiwa D, Yoshikawa H, Kaito T. Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review. Cells, 2019, 8(8): 818.
|
21. |
Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol, 2019, 19(10): 626-642.
|
22. |
Danks L, Komatsu N, Guerrini MM, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis, 2016, 75(6): 1187-1195.
|
23. |
Deschner J, Wypasek E, Ferretti M, et al. Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. J Biomech, 2006, 39(10): 1796-1803.
|
24. |
Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol, 2001, 159(5): 1689-1699.
|
25. |
Matzelle MM, Gallant MA, Condon KW, et al. Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum, 2012, 64(5): 1540-1550.
|
26. |
Quiñonez-Flores CM, González-Chávez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis. J Biomed Sci, 2016, 23(1): 62.
|
27. |
Avouac J, Koumakis E, Toth E, et al. Increased risk of osteoporosis and fracture in women with systemic sclerosis: a comparative study with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2012, 64(12): 1871-1878.
|
28. |
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis, 2020, 79(6): 685-699.
|
29. |
Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging, 2018, 35(2): 163-173.
|
30. |
Clézardin P, Coleman R, Puppo M, et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev, 2021, 101(3): 797-855.
|